Tags

Type your tag names separated by a space and hit enter

Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1α-hydroxy cholecalciferol.
J Ren Nutr. 2013 Jan; 23(1):21-7.JR

Abstract

OBJECTIVE

Hyperphosphatemia in animal models of human renal disease has been linked to increased risk of death. Phosphate binders (e.g., sevelamer hydrochloride) and plant-based, low phosphate diets are used to reduce dietary phosphate load; however, animal models show that treatment with active forms of vitamin D(3) (e.g., calcitriol, a renal disease therapy) renders plant phytate phosphate available for absorption. Using an established chick model, the effectiveness of sevelamer in preventing the apparent absorption of liberated phytate phosphate during active vitamin D use was investigated in two separate experiments.

DESIGN

One-day-old chicks were fed ad libitum a basal diet containing deficient levels of inorganic phosphate (0.13%), but adequate in total phosphate (0.40%, 0.23% as phytate phosphate), with or without the inclusion of sevelamer hydrochloride (a phosphate binder), available inorganic phosphate, or active vitamin D as 1α-(OH) D(3).

MAIN OUTCOME MEASURES

Plasma phosphate (mg/dL), total bone ash (%), and weight gain (g).

RESULTS

Adding inorganic phosphate (0.36%) or 1α-(OH) D(3) increased plasma phosphate 49% and 48%, respectively (P < .0001), and bone ash 23% and 19%, respectively (P < .001). The addition of 1% sevelamer to the basal diet with added inorganic phosphate or 1α-(OH) D(3) significantly decreased plasma phosphate by 28% and 20%, respectively (P < .01).

CONCLUSION

Active vitamin D increased the availability of phytate phosphate for intestinal absorption in an animal model; however, sevelamer effectively reduced the availability of phosphate liberated from phytate. These data imply that sevelamer has phytate phosphate binding efficacy.

Authors+Show Affiliations

Animal Sciences Department, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22406121

Citation

Bobeck, Elizabeth A., et al. "Sevelamer Hydrochloride Binds Phosphate Released From Phytate in Chicks Fed 1α-hydroxy Cholecalciferol." Journal of Renal Nutrition : the Official Journal of the Council On Renal Nutrition of the National Kidney Foundation, vol. 23, no. 1, 2013, pp. 21-7.
Bobeck EA, Meyer KM, Helvig C, et al. Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1α-hydroxy cholecalciferol. J Ren Nutr. 2013;23(1):21-7.
Bobeck, E. A., Meyer, K. M., Helvig, C., Petkovich, M., & Cook, M. E. (2013). Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1α-hydroxy cholecalciferol. Journal of Renal Nutrition : the Official Journal of the Council On Renal Nutrition of the National Kidney Foundation, 23(1), 21-7. https://doi.org/10.1053/j.jrn.2011.12.005
Bobeck EA, et al. Sevelamer Hydrochloride Binds Phosphate Released From Phytate in Chicks Fed 1α-hydroxy Cholecalciferol. J Ren Nutr. 2013;23(1):21-7. PubMed PMID: 22406121.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1α-hydroxy cholecalciferol. AU - Bobeck,Elizabeth A, AU - Meyer,Katie M, AU - Helvig,Christian, AU - Petkovich,Martin, AU - Cook,Mark E, Y1 - 2012/03/09/ PY - 2011/06/15/received PY - 2011/10/31/revised PY - 2011/12/18/accepted PY - 2012/3/13/entrez PY - 2012/3/13/pubmed PY - 2013/5/28/medline SP - 21 EP - 7 JF - Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation JO - J Ren Nutr VL - 23 IS - 1 N2 - OBJECTIVE: Hyperphosphatemia in animal models of human renal disease has been linked to increased risk of death. Phosphate binders (e.g., sevelamer hydrochloride) and plant-based, low phosphate diets are used to reduce dietary phosphate load; however, animal models show that treatment with active forms of vitamin D(3) (e.g., calcitriol, a renal disease therapy) renders plant phytate phosphate available for absorption. Using an established chick model, the effectiveness of sevelamer in preventing the apparent absorption of liberated phytate phosphate during active vitamin D use was investigated in two separate experiments. DESIGN: One-day-old chicks were fed ad libitum a basal diet containing deficient levels of inorganic phosphate (0.13%), but adequate in total phosphate (0.40%, 0.23% as phytate phosphate), with or without the inclusion of sevelamer hydrochloride (a phosphate binder), available inorganic phosphate, or active vitamin D as 1α-(OH) D(3). MAIN OUTCOME MEASURES: Plasma phosphate (mg/dL), total bone ash (%), and weight gain (g). RESULTS: Adding inorganic phosphate (0.36%) or 1α-(OH) D(3) increased plasma phosphate 49% and 48%, respectively (P < .0001), and bone ash 23% and 19%, respectively (P < .001). The addition of 1% sevelamer to the basal diet with added inorganic phosphate or 1α-(OH) D(3) significantly decreased plasma phosphate by 28% and 20%, respectively (P < .01). CONCLUSION: Active vitamin D increased the availability of phytate phosphate for intestinal absorption in an animal model; however, sevelamer effectively reduced the availability of phosphate liberated from phytate. These data imply that sevelamer has phytate phosphate binding efficacy. SN - 1532-8503 UR - https://www.unboundmedicine.com/medline/citation/22406121/Sevelamer_hydrochloride_binds_phosphate_released_from_phytate_in_chicks_fed_1α_hydroxy_cholecalciferol_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1051-2276(12)00002-7 DB - PRIME DP - Unbound Medicine ER -